Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

748205

registered interest
date	04/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Paracetamol
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with the Royal Colleges on the potential effect of pregnant women taking paracetamol and its effect on unborn boys.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	2682
answer	answer is ministerial correction date of answer 12/07/2017 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) continuously monitors the safety of all medicines on the market in the United Kingdom and seeks independent expert advice from the Commission on Human Medicines on important new safety issues. The MHRA is aware of recently published research looking at the effect on male offspring of giving paracetamol to pregnant mice. All new evidence on the safety of paracetamol is kept under close review and this latest study will be carefully considered and any new advice will be communicated.</p><p> </p><p>There have not been any discussions with the Royal Colleges on this issue yet.</p><p> </p><p>Pregnant women should speak to their doctor or midwife before taking any medicine, including paracetamol.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/07/2017 09:46:19 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

748207

registered interest
date	04/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Innovative Medicines and Medical Technology Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to publish the Government's response to the Accelerated Access Review, published in October 2016.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	2743
answer	answer is ministerial correction date of answer 12/07/2017 answer text <p>We are considering the recommendations carefully and will provide a formal response in due course. Taking forward the Accelerated Access Review remains an important manifesto commitment, ensuring patients can access new cost-effective drugs and treatments faster.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/07/2017 09:15:08 answering member 4067 label Biography information for Steve Brine
tabling member	4465 label Biography information for Ronnie Cowan

748209

registered interest
date	04/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to secure an affordable price for Orkambi, to make it available to people with cystic fibrosis.
tabling member constituency	Tooting
tabling member printed	Dr Rosena Allin-Khan
uin	2960
answer	answer is ministerial correction date of answer 12/07/2017 answer text <p>Ministers and Government officials have had a number of discussions with Vertex and NHS England in which the availability of Orkambi for the treatment of cystic fibrosis was raised.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body that develops guidance for the National Health Service on whether new drugs and treatments represent a clinically and cost effective use of resources.</p><p> </p><p>NICE published final guidance on the use of Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis homozygous for the F508del mutation in July 2016 that does not recommend this treatment.</p><p> </p><p>Where NICE has not been able to recommend a treatment, funding decisions should be made by the relevant NHS commissioner, based on an assessment of the available evidence.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/07/2017 09:12:44 answering member 4067 label Biography information for Steve Brine
tabling member	4573 label Biography information for Dr Rosena Allin-Khan